Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EndoCal-D is a branded generic oral mineral supplement developed by Precia Pharma Private Limited, an Indian pharmaceutical company. The formulation primarily features calcium orotate, which is recognized for its high bioavailability and absorption rate (approximately 95%). It is often marketed as a combination brand that includes Vitamin D3 (cholecalciferol) to further enhance intestinal calcium absorption and support bone mineralization. EndoCal-D is indicated for nutrient supplementation and the treatment of calcium deficiency, specifically designed to deliver calcium effectively to tissues to support calcium homeostasis. It is approved and available in the Indian market as part of a portfolio focused on lifestyle disease management.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on EndoCal-D.